Vertex Pharmaceuticals Incorporated (VRTX)
Vertex Pharmaceuticals Incorporated (VRTX) is a healthcare company (biotechnology) based in the United States. The share price is $533.13, down 0.87% on the day, which values the company at $135.17B. Price as of 17 Nov 2026, 17:14 UTC, from Yahoo Finance.
Key facts
- Share price
- $533.13−0.87% today
- Market value
- $135.17B
- P/E ratio
- 34.3×last 12 months
- Forward P/E
- 26.8×
- Funk Score
- 69/100
- Against its own history
- About its usual priceusual price $511.97
- 200-week average
- $429.4724% above
- Sector
- Healthcare
Figures as of . Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.
Vertex Pharmaceuticals Incorporated in more detail
VRTX trades at 34.3× its last twelve months' earnings, 26.8× next year's expected earnings, 10.4× sales. Measured against its own history, the price is 4% above what its usual multiples would imply ($511.97) — about its usual price. It sits 24% above its 200-week average of $429.47.
Over the last five fiscal years Vertex Pharmaceuticals Incorporated has compounded revenue 14.1% a year, earnings per share 8.3% a year, free cash flow 1.3% a year. Its Funk Score is 69 out of 100 (financial strength 9.3, profitability 8.8, growth 5.9, value 3.6, each out of 10).
In its favour: Altman Z in the safe zone; Five straight years of revenue growth.
5 of the superinvestors tracked here hold VRTX, including Tweedy, Browne team (1.1% of the portfolio), Jim Simons (1938–2024) (0.3% of the portfolio), Israel Englander (0.2% of the portfolio).
Superinvestors holding VRTX
5 of the investors tracked here report a position in their latest 13F filing.
- Tweedy, Browne team Tweedy, Browne Company1.11% of portfolio · $13.6M · trimmed · Q3 2026
- Jim Simons (1938–2024) Renaissance Technologies0.28% of portfolio · $207.4M · added · Q3 2026
- Israel Englander Millennium Management0.16% of portfolio · $232.7M · added · Q2 2026
- Ken Griffin Citadel Advisors0.15% of portfolio · $253.5M · added · Q2 2026
- Baillie Gifford team Baillie Gifford & Co0.13% of portfolio · $139.1M · trimmed · Q3 2026
Health Care companies of similar size
- Abbott LaboratoriesABT
- Novo NordiskNVO
- PfizerPFE
- DanaherDHR
- Intuitive SurgicalISRG
- MedtronicMDT
- Bristol-Myers SquibbBMY
- StrykerSYK
- McKessonMCK
- SanofiSNY
- ModernaMRNA
- CVS HealthCVS
Side by side:VRTX vs MDT (Vertex Pharmaceuticals Incorporated vs Medtronic)VRTX vs BMY (Vertex Pharmaceuticals Incorporated vs Bristol-Myers Squibb)VRTX vs ISRG (Vertex Pharmaceuticals Incorporated vs Intuitive Surgical)VRTX vs DHR (Vertex Pharmaceuticals Incorporated vs Danaher)VRTX vs PFE (Vertex Pharmaceuticals Incorporated vs Pfizer)
All health care companies by market valueLargest companies in the United StatesAll stocks A–Z
Vertex Pharmaceuticals Incorporated (VRTX): questions and answers
What is VRTX's P/E ratio?
Vertex Pharmaceuticals Incorporated trades at 34.3× its last twelve months' earnings and 26.8× next year's expected earnings. At its fiscal year-ends over the past 9 years the P/E ranged from 20.5× to 237.2×, with a median of 29.3×.
What is VRTX's PEG ratio?
Vertex Pharmaceuticals Incorporated's PEG ratio is 2.34 — its P/E divided by its expected earnings growth. Around 1 is the classic sign of a price that matches the growth; well above it means the growth is being paid for in advance.
What is Vertex Pharmaceuticals Incorporated's market cap?
Vertex Pharmaceuticals Incorporated is valued at $135.17B at a share price of $533.13.
Is VRTX overvalued or undervalued?
Against its own history, VRTX is about its usual price: the price is 4% above the $511.97 implied by the median multiples it has traded at (price / earnings, price / sales, price / book, price / free cash flow). That compares the stock with its past; it does not say whether the business now deserves a higher or lower multiple.
Is VRTX above its 200-week moving average?
Yes. VRTX is 24.1% above its 200-week average of $429.47. Long-term investors watch that line because strong companies rarely trade below it for long.
How fast is Vertex Pharmaceuticals Incorporated growing?
Over the last five fiscal years Vertex Pharmaceuticals Incorporated's revenue grew 14.1% a year and its earnings per share 8.3% a year; over ten years revenue grew 27.8% a year.
Learn to read these numbers
All stocks guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
- Free cash flow and FCF yield explained
Free cash flow is the cash a business generates from operations minus what it spends on equipment, buildings and other long-lived assets. Free-cash-flow yield divides that cash by the company's market value: $5 billion of free cash flow on a $100 billion company is a 5% yield. It is cash available to owners and lenders, not profit.
Cite this page
Funkfolio, “Vertex Pharmaceuticals Incorporated (VRTX) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/VRTX
Underlying data: Yahoo Finance; company filings with the SEC.